The Malignant Pleural Mesothelioma drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Pleural Mesothelioma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued products.
GlobalData tracks 91 drugs in development for Malignant Pleural Mesothelioma by 81 companies/universities/institutes. The top development phase for Malignant Pleural Mesothelioma is phase ii with 41 drugs in that stage. The Malignant Pleural Mesothelioma pipeline has 83 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Malignant Pleural Mesothelioma pipeline products market are: Pharma Mar, GSK and CStone Pharmaceuticals.
The key targets in the Malignant Pleural Mesothelioma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).
The key mechanisms of action in the Malignant Pleural Mesothelioma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 14 drugs in Phase III. The Malignant Pleural Mesothelioma pipeline products include 15 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Malignant Pleural Mesothelioma pipeline products market including Monoclonal Antibody, and Small Molecule.
Malignant Pleural Mesothelioma overview
Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and nerve pain
For a complete picture of Malignant Pleural Mesothelioma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
